AUR 1001

Drug Profile

AUR 1001

Alternative Names: OX-1406

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoNOX
  • Developer Aura Biopharm
  • Class Monoclonal antibodies
  • Mechanism of Action Glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Antiphospholipid syndrome

Most Recent Events

  • 03 Aug 2016 Preclinical trials in Antiphospholipid syndrome in USA (unspecified route) prior to August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top